Immunotherapy, as the most influential tumor treatment method at present, has comprehensively changed the treatment pattern of advanced non-small cell lung cancer (NSCLC). However, there are still many unresolved issues in the immunotherapy of advanced NSCLC, such as the combination and optimization of immunotherapy combination models, the mechanism and response strategies of resistance in tumor immunotherapy, finding effective biomarkers for immunotherapy, exploring immunotherapy strategies with special population characteristics, and managing the toxic side effects of immunotherapy. This article proposes some issues and perspectives on the current status and future path of immunotherapy for advanced NSCLC, hoping to provide new ideas that are in line with the current immunotherapy for advanced NSCLC, and to provide readers with directions for thinking and future exploration.

non-small cell lung cancer  /  immunotherapy  /  immune checkpoint inhibitors